76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
10X Genomics Inc (Class A)
Closed
SectorHealthcare
14.09 2.62
Overview
Share price change
24h
Min
13.85
Max
14.28
Income | 15M -34M |
|---|---|
Sales | -10M 155M |
Profit margin | -22.183 |
Employees | 1,306 |
EBITDA | -1.5M -39M |
Recommendations | Buy |
|---|---|
12 Months Forecast | -4.75% downside |
Next Earnings | 7 Aug 2025 |
|---|
Market Cap | 361M 1.4B |
|---|---|
Previous open | 11.47 |
Previous close | 14.09 |
News Sentiment
By Acuity
34%
66%
78 / 375 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
10X Genomics Inc (Class A) Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
10X Genomics Inc (Class A) Forecast
Price Target
By TipRanks
-4.75% downside
12 Months Forecast
Average 13.44 USD -4.75%
High 18 USD
Low 9 USD
Based on 10 Wall Street analysts offering 12 month price targets for10X Genomics Inc (Class A) - Dist in the last 3 months.
Sentiment
By Acuity
78 / 375 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About 10X Genomics Inc (Class A)
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
